{
    "clinical_study": {
        "@rank": "50146", 
        "arm_group": [
            {
                "arm_group_label": "Nasal Continuous Positive Airway Pressure (CPAP)", 
                "arm_group_type": "Active Comparator", 
                "description": "After 2 hours evaluation:\nInfants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of  >40% to maintain the targeted saturation of >88% to 92%.\nNon-invasive surfactant treatment (Curosurf\u00ae) 100 mg/kg per dose"
            }, 
            {
                "arm_group_label": "Nasal Intermittent Mandatory Ventilation (IMV)", 
                "arm_group_type": "Active Comparator", 
                "description": "After 2 hours evaluation:\nInfants needed invasive MV or Required a fraction of inspired oxygen of  >40% to maintain the targeted saturation of > 88% to 92%.\nNon-invasive surfactant treatment (Curosurf\u00ae) 100 mg/kg per dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators aimed to compare the efficacy of nasal intermittent mandatory ventilation\n      (IMV) and nasal continuous positive airway pressure (CPAP) in early rescue surfactant\n      treatment in preterm infants."
        }, 
        "brief_title": "Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Noninvasive Ventilation for Respiratory Distress Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Gestational age 26-32 weeks\n\n        The criteria for failure were met by at least 1 of the following:\n\n          -  pH: 7.10 and PaCO2: 70 mm Hg\n\n          -  Recurrent apnea with >3 episodes (Prophylactic caffeine were used in all infants)\n\n          -  Single episode of apnea that required bag-and-mask ventilation\n\n          -  PaO2: 50 mmHg with a fraction of inspired oxygen of >0.5.\n\n        Exclusion Criteria:\n\n          -  Major congenital anomalies\n\n          -  Presence of cardiovascular instability\n\n          -  Intubation at admission to the NICU\n\n          -  Consent not provided or refused"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "2 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741129", 
            "org_study_id": "ZTB2611"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nasal Continuous Positive Airway Pressure (CPAP)", 
                "description": "PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute", 
                "intervention_name": "Nasal CPAP (SLE)", 
                "intervention_type": "Device", 
                "other_name": "SLE 2000, SLE 5000"
            }, 
            {
                "arm_group_label": "Nasal Intermittent Mandatory Ventilation (IMV)", 
                "description": "PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute", 
                "intervention_name": "Nasal IMV (SLE)", 
                "intervention_type": "Device", 
                "other_name": "SLE 2000, SLE 5000"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pulmonary Surfactants"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nasal CPAP", 
            "Nasal IMV", 
            "Surfactant", 
            "Preterm infants"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey", 
                    "zip": "06230"
                }, 
                "name": "Zekai Tahir Burak Maternity Teaching Hospital"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "If infants needed invasive MV or Required a fraction of inspired oxygen of  >40% to maintain the targeted saturation of >88% to 92%, surfactant treatment will give for respiratory distress syndrome (RDS). It means that nasal IMV or CPAP is ineffective.", 
            "measure": "Efficacy of nasal intermittent mandatory ventilation (IMV) and nasal continuous positive airway pressure (CPAP) in early rescue surfactant treatment in preterm infants", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741129"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zekai Tahir Burak Maternity and Teaching Hospital", 
            "investigator_full_name": "Mehmet Yekta", 
            "investigator_title": "Zekai Tahir Burak Maternity and Teaching Hospital, Ankara", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "respiratory insufficiency, pneumothorax", 
            "measure": "Complications of respiratory support", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Zekai Tahir Burak Maternity and Teaching Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mehmet Yekta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}